Variant NM_000492.4:c.1652G>A
| Name | NM_000492.4:c.1652G>A |
| Protein name | NP_000483.3:p.(Gly551Asp) |
| Genomic name (hg19) | chr7:g.117227860G>A UCSC |
| Genomic name (hg38) | chr7:g.117587806G>A UCSC |
| #Exon/intron | exon 12 |
| Legacy Name | G551D |
| Class | disease-causing |
| Subclass | CF-causing |
| WT sequence | GAAGGTGGAATCACACTGAGTGGAG G TCAACGAGCAAGAATTTCTTTAGCA |
| Mutant sequence | GAAGGTGGAATCACACTGAGTGGAG A TCAACGAGCAAGAATTTCTTTAGCA |
![]() |
![]() | dbSNP rs75527207 |
![]() | ![]() |
| Modulator | FDA approval | EMA approval | in vitro / ex vivo data | clinical data |
| IVA | yes | yes | no | yes |
| TEZ-IVA | yes | no | yes | no |
| ELX-TEZ-IVA | yes | no | yes | no |
| VNZ-TEZ-DIVA | yes | no | no | yes |
clinical and functional data presented above are provided by Vertex
| Reference | PMID | Modulator | in vitro / ex vivo data | clinical data | Patient responsiveness |
| Burgel et al., 2024 | 39151434 | ELX-TEZ-IVA | N.D. | yes | yes |
3 individuals carrying this variant are reported in CFTR-NGS catalogue |
| TOTAL NUMBER OF PATIENTS | 95 |
|---|---|
| Asymptomatic compound heterozygote | 3 |
| CF | 73 |
| CFTR-RD | 10
|
| Pending | 3 |
| Pending (NBS) | 6 |
| Color code: non disease-causing < likely benign < VUS < likely pathogenic < disease-causing |
| Phenotype | Patient ID | Variant status | Additional variants |
|---|---|---|---|
| CBAVD | 4706 | heterozygote | CFTR-RD-causing- Undef |
| CBAVD | 1378 | heterozygote | CFTR-RD-causing - Trans |
| CBAVD | 1478 | heterozygote | non-CF- Undef |
| CBAVD | 2353 | heterozygote | varying clinical consequence- Undef |
| Pending (NBS) | 3676 | heterozygote | varying clinical consequence - Trans |
| Pending (NBS) | 3655 | heterozygote | varying clinical consequence - Trans |
| Pending (NBS) | 4030 | heterozygote | CFTR-RD-causing - Trans |
| Pending (NBS) | 3958 | heterozygote | non-CF - Trans |
| Pending (NBS) | 4821 | heterozygote | varying clinical consequence - Trans |
| Pending (NBS) | 562 | heterozygote | VUS3 - Trans |
| CF | 3431 | heterozygote | CF-causing- Undef |
| CF | 3661 | heterozygote | CF-causing- Undef |
| CF | 3717 | heterozygote | CF-causing- Undef |
| CF | 3739 | heterozygote | CF-causing - Trans |
| CF | 3770 | heterozygote | CF-causing- Undef |
| CF | 3777 | heterozygote | CF-causing- Undef |
| CF | 3792 | heterozygote | CF-causing - Trans |
| CF | 3803 | heterozygote | CF-causing - Trans |
| CF | 3858 | heterozygote | CF-causing- Undef |
| CF | 3656 | heterozygote | CF-causing- Undef |
| CF | 3653 | heterozygote | CF-causing- Undef |
| CF | 3470 | heterozygote | CF-causing- Undef |
| CF | 3493 | heterozygote | CF-causing- Undef |
| CF | 3506 | heterozygote | CF-causing- Undef |
| CF | 3524 | heterozygote | CF-causing- Undef |
| CF | 3564 | heterozygote | CF-causing- Undef |
| CF | 3565 | heterozygote | CF-causing- Undef |
| CF | 3575 | heterozygote | CF-causing - Trans |
| CF | 3576 | heterozygote | CF-causing- Undef |
| CF | 3585 | heterozygote | CF-causing - Trans |
| CF | 3861 | heterozygote | CF-causing- Undef |
| CF | 3875 | heterozygote | CF-causing - Trans |
| CF | 4090 | heterozygote | CF-causing- Undef |
| CF | 4091 | heterozygote | CF-causing - Trans |
| CF | 4166 | heterozygote | varying clinical consequence- Undef |
| CF | 4189 | heterozygote | CF-causing- Undef |
| CF | 5783 | heterozygote | varying clinical consequence - Trans |
| CF | 4427 | heterozygote | CF-causing - Trans |
| CF | 4434 | heterozygote | CF-causing - Trans |
| CF | 4056 | heterozygote | CF-causing- Undef |
| CF | 4050 | heterozygote | CF-causing- Undef |
| CF | 3892 | heterozygote | CF-causing- Undef |
| CF | 3904 | heterozygote | CF-causing- Undef |
| CF | 3912 | heterozygote | CF-causing - Trans |
| CF | 3936 | heterozygote | CF-causing- Undef |
| CF | 3937 | heterozygote | CF-causing- Undef |
| CF | 3944 | heterozygote | CF-causing- Undef |
| CF | 3951 | heterozygote | CF-causing- Undef |
| CF | 3995 | heterozygote | CF-causing - Trans |
| CF | 4510 | heterozygote | CF-causing - Trans |
| CF | 4780 | heterozygote | CF-causing - Trans |
| CF | 1164 | heterozygote | CF-causing - Trans |
| CF | 1201 | heterozygote | CF-causing - Trans |
| CF | 1303 | heterozygote | CF-causing- Undef |
| CF | 1608 | heterozygote | CF-causing- Undef |
| CF | 1622 | heterozygote | CF-causing- Undef |
| CF | 5512 | heterozygote | CF-causing - Trans |
| CF | 183 | heterozygote | CF-causing - Trans |
| CF | 242 | heterozygote | CF-causing- Undef |
| CF | 365 | heterozygote | CF-causing - Trans |
| CF | 368 | heterozygote | CF-causing - Trans |
| CF | 729 | heterozygote | CF-causing - Trans |
| CF | 956 | heterozygote | CF-causing - Trans |
| CF | 1623 | heterozygote | CF-causing- Undef |
| CF | 1677 | heterozygote | CF-causing- Undef |
| CF | 2589 | heterozygote | CF-causing- Undef |
| CF | 2598 | heterozygote | CF-causing- Undef |
| CF | 2729 | heterozygote | varying clinical consequence- Undef |
| CF | 2773 | heterozygote | CF-causing - Trans |
| CF | 2810 | heterozygote | CF-causing - Trans |
| CF | 3005 | heterozygote | CF-causing - Trans |
| CF | 3120 | heterozygote | CFTR-RD-causing- Undef |
| CF | 5777 | heterozygote | CFTR-RD-causing - Trans CF-causing - Trans |
| CF | 2426 | heterozygote | varying clinical consequence- Undef |
| CF | 4988 | heterozygote | CFTR-RD-causing- Undef |
| CF | 1889 | heterozygote | CF-causing- Undef |
| CF | 1903 | heterozygote | CF-causing- Undef |
| CF | 1994 | heterozygote | CF-causing- Undef |
| CF | 2250 | heterozygote | CF-causing- Undef |
| CF | 3570 | homozygote | c.1652G>A - p.(Gly551Asp) - Trans |
| CF | 4408 | homozygote | c.1652G>A - p.(Gly551Asp) - Trans |
| CF | 1820 | homozygote | c.1652G>A - p.(Gly551Asp) - Trans |
| CF | 3591 | homozygote | c.1652G>A - p.(Gly551Asp) - Trans |
| Asymptomatic compound heterozygote | 385 | heterozygote | VUS3 - Trans |
| Asymptomatic compound heterozygote | 574 | heterozygote | VUS3 - Trans |
| Asymptomatic compound heterozygote | 3148 | heterozygote | non-CF - Trans |
| Other | 4458 | heterozygote | |
| Other | 1283 | heterozygote | |
| Other | 5522 | heterozygote | CFTR-RD-causing- Undef |
| Bronchiectasis | 1237 | heterozygote | CFTR-RD-causing- Undef |
| Pancreatitis | 4890 | heterozygote | varying clinical consequence- Undef |
| Pancreatitis | 5371 | heterozygote | VUS2- Undef |
| Pending | 4505 | heterozygote | |
| Pending | 2447 | heterozygote | varying clinical consequence- Undef |
| Pending | 5868 | heterozygote | varying clinical consequence- Undef |
| Color code: non disease-causing < likely benign < VUS < likely pathogenic < disease-causing |
| CFTR variants are clustered into five groups (click here for more details about the classification of variants): |
|